[Targeted therapies in pediatric oncology: a new therapeutic approach?].

Article Details

Citation

Copy to clipboard

Jubert C, Geoerger B, Grill J, Hartmann O, Vassal G

[Targeted therapies in pediatric oncology: a new therapeutic approach?].

Arch Pediatr. 2006 Feb;13(2):189-94. Epub 2005 Nov 17.

PubMed ID

16298518 [ View in PubMed

]

Abstract

A multidisciplinary therapeutic approach has led to significant increase in survival of children with cancer, however often with a high rate of severe sequela. Better understanding in tumor cell biology and transformation process allowed to describe active tyrosine kinases (mainly growth factor receptors) as a new target for cancer treatment. This review presents 2 approaches to target receptor tyrosine kinase activity: on one hand, antibodies that target the extracellular domain, the natural ligand binding site, and on the other hand, small inhibiting molecules, such as imatinib, targeted against the activated intracellular receptor tyrosine kinase. We focus on their clinical development and current application in the treatment of childhood cancer. Targeted therapies are in full rise and new perspectives are explored, such as their association to other treatment modalities and the targeting of microenvironment. This new therapeutic approach necessitates well designed clinical trials that include relevant biomarkers to evaluate its real therapeutic potential.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Imatinib	Epithelial discoidin domain-containing receptor 1	Protein	Humans	Unknown	Antagonist	Details